<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04249427</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00104284</org_study_id>
    <nct_id>NCT04249427</nct_id>
  </id_info>
  <brief_title>Erenumab for Idiosyncratic Facial Pain</brief_title>
  <official_title>A Randomized, Double-Blinded, Single Site Study to Evaluate the Efficacy of Erenumab for Treatment of Idiosyncratic Facial Pain Mimicking Rhinosinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Jang, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IV randomized, double-blinded, placebo-controlled study to evaluate the
      efficacy of Erenumab in subjects with midfacial pain or pressure, without clinical or
      radiographic evidence of sinusitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible participants are randomized to receive either Erenumab or placebo by subcutaneous
      injection once monthly for 6 months. Study duration is eight months which includes a 30 day
      screening/lead-in period and 6 monthly treatment visits followed by a follow-up visit one
      month following the last dose of study drug administration. Participants will be expected to
      score on a scale of 1 to 10 their symptoms of facial pain/pressure, nasal congestion, and
      rhinorrhea as well well as any rescue medicines taken for pain each day via a mobile app.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean number of days per month with significant mid-facial pain or pressure</measure>
    <time_frame>Baseline, 1,3, and 6 months</time_frame>
    <description>change in number of days per month with significant mid-facial pain or pressure (defined as greater than 4/10 on scale of 1 - 10) measured by daily dairy completion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in SNOT-22</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by SNOT-22 survey completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Migraine Functional Impact Questionnaire (MFIQ)</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by MFIQ survey completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average number of days per month with significant nasal congestion</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by daily diary completion via mobile app</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average number of days per month with significant rhinorrhea</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by daily diary completion via mobile app</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in doses of rescue pain medications</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by daily diary completion via mobile app</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean daily pain score</measure>
    <time_frame>Baseline, 1, 3 and 6 months</time_frame>
    <description>Measured by daily diary completion via mobile app</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Facial Pain</condition>
  <condition>Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>Erenumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>140mg Erenumab administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered by subcutaneous injection (in the abdomen, thigh, or upper arm), once monthly for six months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erenumab Prefilled Syringe</intervention_name>
    <description>140mg Erenumab, pre-filled syringe given by subcutaneous injection</description>
    <arm_group_label>Erenumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, pre-filled syringe given by subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults 18 - 65 years of age presenting to Duke Head &amp; Neck Surgery and Communications
             Sciences clinic for evaluation of rhinosinusitis and/or facial pain or pressure.

          2. Symptoms are present at least 10 days a month for the last 3 months as reported by
             subject.

          3. Symptoms must include midfacial pain or uncomfortable pressure (may be unilateral or
             bilateral), which is defined as pain in the regions overlying the maxillary, ethmoid,
             frontal sinuses either together or individually.

          4. Clinician determines that the patient has failed medical therapy for rhinosinusitis in
             the last three months, which includes at least 1 month of nasal steroids and one full
             course of antibiotics (at least 7 days).

          5. Nasal endoscopy shows no signs of inflammation (i.e. thick drainage, polyps, watery
             edema in the middle meatus or spheno-ethmoid recess (mild edema permitted)) during
             symptomatic period.

          6. Sinus CT scan within 3 months of enrollment shows no more than scattered minimal
             mucosal edema (&lt;2mm of thickening or mucous retention cyst) with patent infundibula
             bilaterally.

          7. Ability to read/write English.

          8. Has a smart phone, ipod or iPad touch for completion of the EMA on a daily basis.

        Exclusion Criteria:

          1. Hypersensitivity to erenumab or to any of the drug components (acetate, polysorbate,
             and sucrose).

          2. Previous exposure to erenumab or any other anti-CGRPR therapy.

          3. Allergy to latex.

          4. Cluster headache, any other trigeminal autonomic cephalalgia, trigeminal neuralgia or
             any other cranial neuralgia or neuropathy.

          5. Disorders of the temporomandibular joint.

          6. Inability to differentiate facial pain from other headaches.

          7. Non-English speaking or unable to provide written informed consent.

          8. On a preventative migraine medication (see below) in the last month:

               -  Category 1: Divalproex sodium, sodium valproate

               -  Category 2: Topiramate

               -  Category 3: Beta blockers (for example: atenolol, bisoprolol, metoprolol,
                  nadolol, ebivolol, pindolol, propranolol, timolol)

               -  Category 4: Tricyclic antidepressants (for example: amitriptyline, nortriptyline,
                  protriptyline)

               -  Category 5: Serotonin-norepinephrine reuptake inhibitors (for example:
                  venlafaxine, desvenlafaxine, duloxetine, milnacipran)

               -  Category 6: Flunarizine, verapamil

               -  Category 7: Lisinopril, candesartan

          9. Received botulinum toxin (Botox) to the head and neck in the last four months.

         10. More than one surgery of the nose or sinuses.

         11. Prior interventional pain procedure to the head (e.g. trigeminal nerve block).

         12. Chronic pain syndrome or other pain disorder (e.g. fibromyalgia).

         13. History of liver failure.

         14. History of malignancy in the last five years except non-melanoma skin cancers,
             cervical or breast ductal carcinoma in situ.

         15. History of seizure disorder or other significant neurological conditions other than
             migraine, with the exception of childhood febrile seizure.

         16. Myocardial infarction (MI), stroke, transient ischemic attack (TIA), unstable angina,
             or coronary artery bypass surgery or other revascularization procedure within 12
             months prior to screening.

         17. History or evidence of any other unstable or clinically significant medical condition
             that in the opinion of the sponsor-investigator/ Principal Investigator, would pose a
             risk to subject safety or interfere with the study evaluation, procedures or
             completion.

         18. Evidence of drug or alcohol abuse or dependence within 12 months prior to screening,
             based on medical records or patient self-report.

         19. Pregnant or breastfeeding, or expecting to conceive during the study, including
             through 16 weeks after the last dose of investigational product or placebo

         20. Female subject of childbearing potential who is unwilling to use an acceptable method
             of effective contraception during treatment with investigational product or placebo
             through 16 weeks after the last dose of investigational product. Female subjects not
             of childbearing potential are defined as any female who is post-menopausal by history,
             defined as:

               -  Age â‰¥ 55 years with cessation of menses for 12 or more months, OR

               -  Age &lt; 55 years but no spontaneous menses for at least 2 years, OR

               -  Underwent bilateral oophorectomy, bilateral salpingectomy, or hysterectomy

         21. Unlikely to be able to complete all protocol required study visits or procedures.

         22. Currently receiving treatment in another investigational device or drug study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Jang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victoria Johnson</last_name>
    <phone>919-681-4595</phone>
    <email>vaj5@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Walker</last_name>
    <phone>919-684-1732</phone>
    <email>amy.walker1@duke.edu</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>David Jang, M.D.</investigator_full_name>
    <investigator_title>Associate Professor of Head and Neck Surgery and Communication Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
    <mesh_term>Facial Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erenumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

